30260016|t|In silico evidence of direct interaction between statins and beta-amyloid.
30260016|a|INTRODUCTION: Aggregation of amyloid-beta (Abeta) peptides represents a crucial step in the pathogenesis of Alzheimer disease (AD). Compelling evidence from preclinical studies has established that statins may reduce amyloidogenesis and Abeta-mediated neurodegeneration, supporting a potential role of statin treatment in the prevention of AD. Different statins have been shown to interfere indirectly with Abeta production and clearance through either cholesterol-dependent or cholesterol-independent mechanisms. However, whether there may be a direct interaction between statins and Abeta metabolism is still unclear. MATERIALS AND METHODS: To test the possible direct interaction between statins and Abeta, we performed an in silico study by testing the orientation of different ligands, including statins and sulindac (the standard ligand of Abeta), in the Abeta active site using molecular operating environment (MOE) software. RESULTS: Docking experiments showed that all the tested statins could directly interact with Abeta protofibrils. Among statins, pitavastatin had the strongest interaction with Abeta (pki  = 7.66), followed by atorvastatin (pk i  = 7.63), rosuvastatin (pk i  = 6.99), fluvastatin (pk i =  6.96), pravastatin (pk i  = 6.46), lovastatin (pk i  = 6.37), and simvastatin (pk i  = 5.90). According to the above-mentioned results, pitavastatin, atorvastatin, rosuvastatin, and fluvastatin had a stronger binding to Abeta compared with the standard ligand sulindac (pk i  = 6.62). CONCLUSION: This study showed a direct interaction between statins and Abeta protofibrils, which may underlie the protective role of this widely used class of drugs against amyloidogenesis and Abeta-mediated neurodegeneration.
30260016	104	116	amyloid-beta	Gene	351
30260016	118	123	Abeta	Gene	351
30260016	183	200	Alzheimer disease	Disease	MESH:D000544
30260016	202	204	AD	Disease	MESH:D000544
30260016	292	307	amyloidogenesis	Disease	
30260016	312	317	Abeta	Gene	351
30260016	327	344	neurodegeneration	Disease	MESH:D019636
30260016	415	417	AD	Disease	MESH:D000544
30260016	482	487	Abeta	Gene	351
30260016	528	539	cholesterol	Chemical	MESH:D002784
30260016	553	564	cholesterol	Chemical	MESH:D002784
30260016	660	665	Abeta	Gene	351
30260016	778	783	Abeta	Gene	351
30260016	888	896	sulindac	Chemical	MESH:D013467
30260016	921	926	Abeta	Gene	351
30260016	936	941	Abeta	Gene	351
30260016	1101	1106	Abeta	Gene	351
30260016	1136	1148	pitavastatin	Chemical	MESH:C108475
30260016	1184	1189	Abeta	Gene	351
30260016	1217	1229	atorvastatin	Chemical	MESH:D000069059
30260016	1246	1258	rosuvastatin	Chemical	MESH:D000068718
30260016	1275	1286	fluvastatin	Chemical	MESH:D000077340
30260016	1303	1314	pravastatin	Chemical	MESH:D017035
30260016	1331	1341	lovastatin	Chemical	MESH:D008148
30260016	1362	1373	simvastatin	Chemical	MESH:D019821
30260016	1432	1444	pitavastatin	Chemical	MESH:C108475
30260016	1446	1458	atorvastatin	Chemical	MESH:D000069059
30260016	1460	1472	rosuvastatin	Chemical	MESH:D000068718
30260016	1478	1489	fluvastatin	Chemical	MESH:D000077340
30260016	1516	1521	Abeta	Gene	351
30260016	1556	1564	sulindac	Chemical	MESH:D013467
30260016	1652	1657	Abeta	Gene	351
30260016	1754	1769	amyloidogenesis	Disease	
30260016	1774	1779	Abeta	Gene	351
30260016	1789	1806	neurodegeneration	Disease	MESH:D019636
30260016	Association	MESH:D019636	351
30260016	Association	MESH:C108475	MESH:D013467
30260016	Association	MESH:D000069059	351
30260016	Association	MESH:D000068718	MESH:D013467
30260016	Association	MESH:D000069059	MESH:D013467
30260016	Association	MESH:D000544	351
30260016	Association	MESH:D000077340	351
30260016	Association	MESH:D000077340	MESH:D013467
30260016	Bind	MESH:D013467	351
30260016	Association	MESH:D002784	351
30260016	Association	MESH:C108475	351
30260016	Association	MESH:D000068718	351
30260016	Association	MESH:D017035	351

